5th Sep 2005 07:00
Oxford Biomedica PLC05 September 2005 FOR IMMEDIATE RELEASE 5 SEPTEMBER 2005 OXFORD BIOMEDICA PLC NOTICE OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2004 Oxford, UK: 5 September 2005 - Oxford BioMedica (LSE:OXB.L), the leading genetherapy company, announces that it will be releasing its interim results for thesix months ended 30 June 2005 on Tuesday, 20 September 2005. Meetings: An analyst briefing will be held at 10:00 am on the day. The venue for themeeting will be Buchanan Communications, 107 Cheapside, London EC2V 6DN. Web cast: Simultaneously to the analyst briefing, there will be a live audio web cast ofthe results presentation. To connect to the web cast facility, please go to the Company's website:http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:50 am) before thestart of the briefing. This will also be available for replay shortly after thepresentation. -Ends- For further information, please contact:Oxford BioMedica plc:Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000City/Financial Enquiries:Lisa Baderoon/ Mark Court/ Mary-Jane JohnsonBuchanan Communications Tel: +44 (0)20 7466 5000Scientific/Trade Press Enquiries:Sue Charles/ Katja Stout/ Ashley LillyNorthbank Communications Tel: +44 (0)20 7886 8150 Notes to editors 1. Oxford BioMedicaOxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment of novel gene-based therapeutics with a focus on the areas ofoncology and neurotherapy. The Company was established in 1995 as a spin outfrom Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-houseclinical, regulatory and manufacturing know-how. In oncology, the pipelineincludes an immunotherapy and a gene therapy in multiple Phase II trials, and apreclinical targeted antibody therapy in collaboration with Wyeth. Inneurotherapy, the Company's lead product is a gene therapy for Parkinson'sdisease, which is expected to enter clinical trials in 2006, and four furtherpreclinical candidates. The Company is underpinned by over 80 patent families,which represent one of the broadest patent estates in the field. The Company has a staff of approximately 65 split between its main facilities inOxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Viragen,MolMed and Kiadis; and has licensed technology to a number of companiesincluding Merck & Co, Biogen Idec and Pfizer.Further information is available at http://www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica